-
California is 1st state to require pharmacists to report errors
California is the first state to require pharmacists to report every prescription mistake. -
Walgreens walkout enters last day: 5 notes
After seeing success from CVS pharmacy workers calling out of work over staffing concerns in Kansas City, Walgreens employees organized a walkout — but it's unclear whether the scattered labor action will result in change. -
Employer coverage of weight-loss drugs set to double in 2024
Forty-three percent of employers plan to cover weight loss drugs in 2024, nearly double the proportion of employers that cover them now, according to newly released survey findings from Accolade. -
Mark Cuban's pharmacy racks up collaborators
Nearly two years after Mark Cuban launched a mail-order pharmacy with low-cost medications, the entrepreneur and "Shark Tank" star has secured more than a dozen collaborators. -
DEA, HHS issue 2nd extension of controlled substances via telehealth
The U.S. Drug Enforcement Agency is, for a second time, extending clinicians' ability to prescribe controlled substances using telehealth services, according to a revised rule the agency published. -
5 drugs now in shortage
Since mid-September, drugmakers have reported five new drug shortages, including medications for lung cancer, hypertension and eye infections. -
Walgreens pharmacists plan walkout
An unclear number of Walgreens pharmacies might close Oct. 9-11 after pharmacists shared plans through social media apps, emails and fliers to stage a walkout, according to CNN. -
Minnesota system buys independent pharmacy
Staples, Minn.-based Lakewood Health System is acquiring a local pharmacy. -
Cancer drug study partially halted after patient death
After a study participant died from a severe and rare inflammatory syndrome, the FDA placed a partial clinical hold on a France-based drugmaker's cancer drug trial. -
Mark Cuban's drug company, caregiver app team up
Mark Cuban Cost Plus Drug Co. recently penned a deal with Avanlee Care, which runs an app designed to help caregivers for elderly patients. -
Walmart: Ozempic leading to fewer food purchases
Walmart is experiencing less food demand from individuals taking GLP-1s such as Ozempic or Wegovy, Bloomberg reported Oct. 4. -
Cancer drug shortage slightly eases
The national shortage of multiple cancer therapies is marginally improving compared to early summer, according to an Oct. 5 update from the National Comprehensive Cancer Network. -
Kaiser closes some outpatient pharmacies amid strike
As about 75,000 Kaiser Permanente workers strike in six states, the Oakland, Calif.-based system has temporarily closed at least 18 outpatient pharmacies across four states. -
FDA probes phony Ozempic schemes
The FDA has started investigating schemes to sell counterfeit versions of Ozempic to unsuspecting pharmacies, according to an Oct. 4 industry alert obtained by CBS News. -
Study links Ozempic with stomach paralysis
The active ingredients of Ozempic, Wegovy and Saxenda are associated with stomach paralysis, according to a study published Oct. 5 in JAMA. -
AbbVie's oral cancer drug trial shows it may provide 'anti-tumor immunity'
Research for a new oral cancer medication from pharmaceutical giant AbbVie yielded positive preclinical data that shows it "enhances anti-tumor immunity," according to an Oct. 4 news release. -
Moderna to move forward with combo flu, COVID-19 shot
Moderna is moving forward with plans to develop a combination vaccine for flu and COVID-19 after early-stage studies yielded positive results, the company said Oct. 3. -
31 drugmakers, biotechs form pro-M&A group
More than two dozen life science, pharmaceutical and biotech organizations partnered Oct. 4 to build a coalition advocating for mergers and acquisitions in the life sciences industry. -
Paxlovid reduces COVID-19 mortality only among highest risk patients: Study
Paxlovid (nirmatrelvir-ritonavir), a COVID-19 antiviral treatment, was found to be effective in reducing hospitalizations and deaths only among "the most clinically extremely vulnerable individuals," according to a study published Oct. 2 in JAMA. -
Mark Cuban takes aim at pink tax
As Mark Cuban Cost Plus Drug Co. continues to make waves in the pharmaceutical market, it will soon begin to offer Clomid, a common fertility drug, to its customers.
Page 44 of 50